Need Help?

Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Key Points• Multiple mechanisms of acquired CD19 mutations and splicing contribute to CD19 loss and relapse to blinatumomab.• Identification of CD19 ex2part levels represents a new biomarker predictive of resistance or likely failure of blinatumomab

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001005729 Illumina HiSeq 2000 56
EGAD00001005730 Illumina HiSeq 2000 60
EGAD00001005731 Illumina HiSeq 2000 41
EGAD00001005732 Illumina HiSeq 2000 10
EGAD00001005733 Illumina HiSeq 2000 10
Publications Citations
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Blood 137: 2021 471-484